Physician profile
Foad Moazez
NPI 1134122203
$6,524.50
in general payments reported to CMS, 2019-2025
16 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,699 · 2020: $260 · 2021: $402 · 2022: $803 · 2023: $296 · 2024: $314 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,310 · Travel and Lodging: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.71 |
| Travel and Lodging | $1,049.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,551.81 | 2019-2020 | |
| Medtronic, INC. | $2,033.26 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan |
| Boston Scientific Corporation | $309.19 | 2022-2024 | Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor |
| Biotronik INC. | $269.33 | 2019-2022 | |
| Abbott Laboratories | $263.10 | 2020-2023 | Mitraclip |
| Amgen INC. | $197.80 | 2025 | Repatha, Repatha |
| Impulse Dynamics (USA) INC. | $191.25 | 2022-2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $123.74 | 2019-2025 | Camzyos |
| Pfizer INC. | $123.55 | 2023 | |
| Amarin Pharma, INC. | $112.10 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.93 | 2021-2024 | Lifevest |
| Philips North America LLC | $70.45 | 2022 | |
| Alnylam Pharmaceuticals INC. | $70.06 | 2025 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $54.34 | 2025 | |
| Esperion Therapeutics, INC. | $21.96 | 2024 | Nexletol |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $20.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Foad Moazez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.